Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study-Reference-Cited by-同舟云学术

Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study

Published:2020-10-30 Issue:12 Volume:40 Page:1155-1166
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Zheng Shuai,Shao Feng,Ding Yu,Fu Zhenzhen,Fu Qi,Ding Sijia,Xie Lijun,Chen Juan,Zhou Sufeng,Zhang Hongwen,Zhou Hongwen,Chen Yang,Sun Caixia,Zhu Jing,Zheng Xuqin,Yang Tao^ORCID

Funder

Yabao Pharmaceutical R&D Co., Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-020-00971-x.pdf

Reference17 articles.

1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98.

2. Upadhyay J, Polyzos SA, Perakakis N, et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism. 2018;78:13–42.

3. Sternisha SM, Miller BG. Molecular and cellular regulation of human glucokinase. Arch Biochem Biophys. 2019;663:199–213.